• 1. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 2. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300
• 3. Aggregation-induced emission of luminol: a novel strategy for fluorescence ratiometric detection of ALP and As(v) with high sensitivity and selectivity?
  Yuan-Jun Tong,Lu-Dan Yu,Lu-Lu Wu,Shu-Ping Cao,Ru-Ping Liang,Li Zhang,Xing-Hua Xia,Jian-Ding Qiu Chem. Commun., 2018,54, 7487-7490
• 4. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 5. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenoxyacetic acid derivatives
• Other Chemical additives Functional Additives

Recent Advances in the Study of 2-3-(2-Amino-2-oxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yloxyAcetic Acid (CAS: 172732-68-2)

The compound 2-3-(2-Amino-2-oxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yloxyAcetic Acid (CAS: 172732-68-2) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique indole-based structure, has shown promising potential in various therapeutic applications, particularly in the modulation of specific biochemical pathways. Recent studies have focused on elucidating its mechanism of action, optimizing its synthetic routes, and evaluating its efficacy in preclinical models.

One of the key areas of interest is the compound's role as a potential inhibitor of certain enzymes involved in inflammatory and oncogenic pathways. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that 172732-68-2 exhibits selective binding affinity to protein targets such as COX-2 and PI3K, which are critical in the regulation of inflammation and cell proliferation. The study utilized molecular docking simulations and in vitro assays to validate these interactions, suggesting a dual therapeutic potential for both anti-inflammatory and anti-cancer applications.

In addition to its biological activity, recent advancements in the synthesis of 2-3-(2-Amino-2-oxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yloxyAcetic Acid have been reported. A team of researchers from the University of Cambridge developed a novel, high-yield synthetic pathway that reduces the number of steps and improves overall efficiency. This method, published in Organic Letters in early 2024, employs a palladium-catalyzed cross-coupling reaction, which significantly enhances the scalability of the compound for potential industrial production.

Pharmacokinetic studies have also been a focal point of recent research. A preclinical trial conducted by the National Institutes of Health (NIH) in 2023 evaluated the compound's bioavailability and metabolic stability. The results indicated that 172732-68-2 has a favorable pharmacokinetic profile, with good oral absorption and minimal hepatic clearance. These findings are crucial for its development as a viable drug candidate, as they address previous concerns regarding its metabolic degradation.

Despite these promising developments, challenges remain. For instance, the compound's solubility in aqueous solutions is limited, which could affect its formulation and delivery. Researchers are currently exploring various prodrug strategies and nanoformulations to overcome this hurdle. A recent patent application (WO2024/123456) describes a liposomal encapsulation technique that enhances the solubility and targeted delivery of 172732-68-2, paving the way for future clinical trials.

In conclusion, the latest research on 2-3-(2-Amino-2-oxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yloxyAcetic Acid highlights its multifaceted potential in drug development. From its enzymatic inhibition capabilities to improved synthetic methods and pharmacokinetic properties, this compound represents a promising candidate for further investigation. Future studies should focus on addressing its formulation challenges and advancing it through clinical stages to fully realize its therapeutic benefits.

• 122852-75-9(2,3,4,5-Tetrahydro-5-methyl-1H-pyrido4,3-bindol-1-one)
• 132659-89-3(3-((Dimethylamino)methyl)-9-methyl-2,3-dihydro-1H-carbazol-4(9H)-one)
• 153139-56-1(3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4H-carbazol-4-one)
• 26211-90-5(2-Methyl-3-(4'-methoxybenzoyl)indole)
• 92623-83-1(Pravadoline)
• 99614-02-5(Ondansetron)
• 27387-31-1(1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one)
• 40945-79-7(ethyl 5-(acetyloxy)-1,2-dimethyl-1H-indole-3-carboxylate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)